Wells Fargo lowered the firm’s price target on Eli Lilly (LLY) to $970 from $1,000 and keeps an Overweight rating on the shares. The firm ...

Mounjaro and Zepbound have shown impressive prescription growth trends ... week increase to 212,962 scripts in the same period. These products have positioned Eli Lilly as a leader in the rapidly ...

Mounjaro and Zepbound have shown impressive prescription growth trends, with Mounjaro experiencing ... saw a 20.7% week-over-week increase to 212,962 scripts in the same period. These products have ...

Advocates say microdosing reduces costs and side effects while maintaining weight loss, then can help with weight maintenance ...

Eli Lilly & Co. said Thursday that its Type 2 diabetes drug Mounjaro and its weight-loss and diabetes drug Zepbound drove a 45% increase in fourth-quarter revenue to $13.53 billion. The drugmaker ...

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...

shares of Lilly have dropped by about 13%. The primary reason the stock has been sliding is due to some inconsistent growth trends between Mounjaro and Zepbound over the last quarter. But as I ...

Lilly didn’t mince words about what sparked that growth, pointing to an impressive 60% sales leap for its type 2 diabetes blockbuster Mounjaro, which brought home $3.5 billion over the last ...